Bipar Sciences

BiPar Sciences was a Brisbane, California biopharmaceutical company developing a tumor-selective class of PARP (poly ADP-ribose polymerase) inhibitors for cancer therapy. Its lead candidate, BSI-201 (iniparib), was in mid-stage trials for advanced breast, ovarian, and other tumors. Backed by Canaan Partners, Vulcan Capital, PolyTechnos, Asset Management Company, and Quantum Technology Partners, BiPar was acquired by Sanofi-Aventis for roughly $500 million in April 2009 and no longer operates as an independent company. It was surfaced as a Canaan Partners portfolio company and added to the API Evangelist network as a stub; enrichment finds no public developer or API surface.

Bipar Sciences is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Oncology, Pharmaceuticals, and PARP Inhibitors.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-21 · rubric v0.12.0

0 APIs

Company Biopharmaceutical Oncology PharmaceuticalsPARP InhibitorsClinical Trials Acquired Life Sciences

Kin Score

Kin Score How this is scored →
scored 2026-08-21 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/bipar-sciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: bipar-sciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/bipar-sciences.png
name: Bipar Sciences
description: BiPar Sciences was a Brisbane, California biopharmaceutical company developing a tumor-selective class of PARP
  (poly ADP-ribose polymerase) inhibitors for cancer therapy. Its lead candidate, BSI-201 (iniparib), was in mid-stage trials
  for advanced breast, ovarian, and other tumors. Backed by Canaan Partners, Vulcan Capital, PolyTechnos, Asset Management
  Company, and Quantum Technology Partners, BiPar was acquired by Sanofi-Aventis for roughly $500 million in April 2009 and
  no longer operates as an independent company. It was surfaced as a Canaan Partners portfolio company and added to the API
  Evangelist network as a stub; enrichment finds no public developer or API surface.
url: https://raw.githubusercontent.com/api-evangelist/bipar-sciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Oncology
- Pharmaceuticals
- PARP Inhibitors
- Clinical Trials
- Acquired
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/bipar-sciences"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/bipar-sciences/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/bipar-sciences/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.